Brief: Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing
13/05/2026 13:12
May 13 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN BIOTECH INC - TO UNBLIND MIRACLE TRIAL DATA BEFORE JUNE 30, 2026 - SEC FILING MOLECULIN BIOTECH INC - MIRACLE TRIAL ON TRACK TO COMPLETE PART A RECRUITMENT IN Q3 2026 - SEC FILING Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM